QMS Medical Q1FY27 Revenue Up 22% YoY

Conducted 11,497 B2B health camps during Q1FY27
Serves 5.7 million+ customers across 5,000+ serviceable pin codes
Maintains 900+ SKUs covering diverse therapeutic and medical categories
Works with 130+ institutional clients including 50+ leading pharma companies
Engages with 1 million+ doctors nationwide
Key drivers: Expanding distribution network, Q-Devices portfolio, digital platforms (QMSMEDS, e-Grameen), deeper pharma partnerships, and scaling healthcare camp operations

Products Business: Revenue of Rs 33 crore in Q1FY27 including Q-Devices
B2B Sales (Pharma & Hospitals): Revenue of Rs 24 crore in Q1FY27
Point-of-Care: Revenue of Rs 9 crore in Q1FY27
E-Commerce (QMSMEDS): Revenue of Rs 0.16 crore in Q1FY27
Services Business: Emerging as key growth engine driven by Patient Support Programs and healthcare camp operations

Revenue: Rs 56.9 crore (22% YoY growth from Rs 46.5 crore in Q1FY26, 28% QoQ growth from Rs 44.4 crore in Q4FY26)
EBITDA: Rs 8.3 crore (27% YoY growth from Rs 6.5 crore in Q1FY26, 41% QoQ growth from Rs 5.9 crore in Q4FY26)
PAT: Rs 4.0 crore (25% YoY growth from Rs 3.2 crore in Q1FY26, 110% QoQ growth from Rs 1.9 crore in Q4FY26)
EPS: Rs 2.05 (compared to Rs 2.20 in Q1FY26 and Rs 0.97 in Q4FY26)
Margins: EBITDA Margin 14.6% (vs 14.1% YoY, 13.3% QoQ), PAT Margin 7.0% (vs 6.8% YoY, 4.2% QoQ)
Drivers: Higher revenue growth, operational efficiencies
Key Risks: Not explicitly disclosed in presentation

Capital Expenditure: Not specified for current period
Operating Cash Flow: Rs 19.4 crore generated in FY26
Free Cash Flow: Not specified
Net Debt Movement: Not specified
Investment Rationale: Focus on capacity expansion, technology upgrades, and strategic acquisitions

Acquired 76% stake in Saarathi Healthcare Pvt Ltd (pioneer in Patient and Disease Management Services)
Expect to acquire balance stake in Saarathi by end of Q2FY27
Proprietary integrated digital health application for patient management
Q-Devices brand launched in 2023 offering medical/wellness devices
Digital ecosystem tracks 10 lakh+ patients and 100+ camps with real-time analytics
Expected impact: Strengthen capabilities in disease management and Patient Support Programs
Strategic Rationale: Addressing entire patient journey more comprehensively, expanding into high-growth services

Total Indian Pharma Market estimated at INR 2.4 lakh crore in 2024 (source: IQVIA report)
Retail Sector may account for estimated Rs 1.9 lakh crore
Key Drivers: Regulatory shift limiting direct promotions, market transition from unorganized to organized players, chronic disease surge, digital innovation, government support through policies like Ayushman Bharat, patient empowerment
Impact on Company: Growing demand for Patient Support Programs and structured health camp services

Strategic Outlook: "Q1FY27 marks a strong start to the year for QMS Medical Allied Services, reflecting the strength of our integrated healthcare business model and the investments made over the past year" - Mahesh Makhija, Founder, Chairman and Managing Director
Focus remains on scaling Patient Support Programs, strengthening strategic partnerships, expanding Q-Devices and Point-of-Care offerings, and leveraging technology platform
FY Guidance: Not explicitly provided
Market Share Targets: Not specified
Risks and Opportunities: Not explicitly highlighted

Founded in 1994, grown from pharma marketing solutions provider to integrated healthcare partner
Mission: To provide patients, doctors, and institutions with best-in-class medical products and services
Vision: To revolutionize healthcare by providing comprehensive, technology-driven solutions
30+ years industry experience in medical device distribution for global brands like 3M, Heine
CDSCO license holder creating high entry barrier
Migrated to NSE Main Board on June 18, 2026
Listed on NSE Emerge in 2022